2Hasan UA, Abai AM, Harper DR, et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines[J]. J Immunol Methods, 1999, 229(1-2): 1-22.
3Roitt IM, Delves PJ. Encyclopedia of Immunology[M]. Great Britain: Academic Press, 1992. 1548-1549.
4Arvin AM, Mallory S, Moffat JF. Development of recombinant varicella-zoster virus vaccines[J]. Contrib Microbiol, 1999, 3:193-200.
5Stasikova J, Kutinova L, Smahel M, et al. Immunization with Varicella-zoster virus glycoprotein E expressing vectors: Comparison of antibody response to DNA vaccine and recombinant vaccinia virus[J]. Acta Virol, 2003,47(1): 1-10.
6Caleo M, Menna E, Chierzi S, et al. Brain-derived neurotrophic factor is an anterograde survival factor in the rat visual system [J]. Curr Biol, 2000, 10(19): 1155-1161.
7Haumont M, Jurdan M, Kangro H, et al. Neutralizing antibody responses induced by varicella-zoster virus gE and gb glycoproteins following infection, reactivation or immunization[J]. J Med Virol, 1997, 53(1): 63-68.
8Mc Crary M. Severson J. Tyring SK. Varcella- zoster virus,JAAD. 1999;41:1-4
9Wharton M. The epidemiology of varcella - zoster virus infection, Infect Dis Clin N Am, 1996;10:571-581
10Whitley RJ, Scokg S J, Dolin R, et al. Early vidarabine therapy to control the complication of herpes zoster in immunosuppressed patients. N Engl J Med, 1982;307:971-975
